

STARSOURCE MULTITRADE LIMITED

(Formerly known as Chemo Pharm Laboratories Limited)

(CIN: L46900MH1942PLC003556)

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd, Karnik Road, Chikan Ghar,
Kalyan, Dist. Thane – 421301

Corporate Office: Office No 1016, North Plaza, Near D Mart, Visat Gandhinagar Highway,
Motera, Ahmedabad, Gujarat, India – 380005

Tel. No.:022-22078382 Website: www.thechemopharmalaboratoriesltd.com

Email : chemopharmalaboratorieslimited@gmail.com

Date: November 13, 2025

To,
Bombay Stock Exchange Limited
Department of Corporate Services,
25th Floor, P. J. Towers, Dalal Street,
Mumbai-400001

Script Id: 506365

ISIN: INE320M01019

Subject: Outcome of Board Meeting held on Thursday, November 13, 2025.

Dear Sir / Madam,

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulations, 2015, we wish to inform you that Board of Directors of the Company at their meeting held on Thursday, **November 13, 2025** at the Registered Office of the Company, inter alia, have considered and approved the following:

1. Un-Audited Financial Results of the Company for the quarter and Half Year ended September 30, 2025.
2. Limited Review Report on the Un-audited Financial Results of the Company for the quarter ended on September 30, 2025.

The Un-audited Financial Results (Standalone and Consolidated) for the quarter ended September 30, 2025 along with the limited review reports thereon are enclosed herewith.

The aforesaid information is also available on website of the company www.thechemopharmalaboratoriesltd.com

The meeting commenced at 4 PM and concluded at **4:15 PM.**

The same may please be taken on record.

Thanking You.
Yours Faithfully,

FOR STARSOURCE MULTITRADE LIMITED
(Formerly known as CHEMO PHARMA LABORATORIES LIMITED)



RUCHIT MEHTA
Managing Director & Chief Executive Officer
DIN: 08810586

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30TH SEPTEMBER, 2025

(Rupees in Thoudsand)

Sr. No	Particulars	Quarter ended			Six Months Ended		Year ended
		30th Sep 2025	30th June 2025	30th Sep 2024	30th Sep 2025	30th Sep 2024	31st March 2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from operations	5256.56	0.00	0.00	5256.56	0.00	0.00
II	Other income	0.00	207.12	6310.00	207.12	9327.00	6198.00
III	TOTAL REVENUE	5256.56	207.12	6310.00	5463.68	9327.00	6198.00
IV	EXPENSES						
	(1) Cost of materials consumed	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Purchases of stock-in-trade	3765.35	0.00	0.00	3765.35	0.00	0.00
	(3) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(4) Employee benefits expense	216.00	240.60	54.00	456.60	108.00	216.00
	(5) Finance costs	0.59	5.38	0.00	5.97	0.00	0.00
	(6) Depreciation and amortisation expense	0.00	0.00	14.00	0.00	27.00	54.00
	(7) Administrative & Other expenses	294.48	118011.79	142.00	118306.27	626.00	947.00
	TOTAL EXPENSES	4276.42	118257.77	210.00	122534.19	761.00	1217.00
V	Profit/(Loss) before exceptional items & tax	980.14	(118050.65)	6100.00	(117070.51)	8566.00	4981.00
VI	Exceptional items (net charge)	0.00	0.00	0.00	0.00	0.00	0.00
VII	Net Profit before ExtraOrdinary Items & Tax	980.14	(118050.65)	6100.00	(117070.51)	8566.00	4981.00
VIII	Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
IX	Profit before Tax	980.14	(118050.65)	6100.00	(117070.51)	8566.00	4981.00
X	Tax Expenses						
	(1) Current tax	0.00	0.00	0.00	0.00	0.00	1993.00
	(2) Tax Aduastment Previous Year	0.00	0.00	0.00	0.00	0.00	0.00
	(3) Deferred tax credit/(charge)	0.00	0.00	0.00	0.00	0.00	(435.00)
	(4) MAT Credit Entitlement	0.00	0.00	0.00	0.00	0.00	0.00
XI	PROFIT/Loss FOR THE PERIOD from continious operations	980.14	(118050.65)	6100.00	(117070.51)	8566.00	3423.00
XII	PROFIT/Loss from dis-continious operations	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Tax expenses for dis-continious operations	0.00	0.00	0.00	0.00	0.00	0.00
XIV	PROFIT/Loss FOR THE PERIOD from dis-continious operations	0.00	0.00	0.00	0.00	0.00	0.00
XV	PROFIT/Loss FOR THE PERIOD	980.14	(118050.65)	6100.00	(117070.51)	8566.00	3423.00
XVI	OTHER COMPREHENSIVE INCOME						
	A(i)Items that will not be reclassified subsequently to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to Items that will not be reclassified subsequently to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
XVII	TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (Comprising Profit/(Loss) and other comprehensive income for the period	980.14	(118050.65)	6100.00	(117070.51)	8566.00	3423.00
XVII	Earnings per equity share						
	(1) Basic	0.65	-78.70	4.07	-78.05	5.71	2.28
	(2) Diluted	0.65	-78.70	4.07	-78.05	5.71	2.28

FOR STARSOURCE MULTITRADE LIMITED (Formerly known as CHEMO PHARMA LABORATORIES LIMITED)

Date: 13.11.2025
Place: Mumbai



Mehta Ruchit P.

RUCHIT MEHTA
MD & CEO
DIN: 08810586

**STANDALONE STATEMENT OF ASSETS & LIABILITIES FOR THE HALF YEAR ENDED
AS ON 30TH SEPTEMBER, 2025**

(Rupees in Thousands)

Sr. No	PARTICULARS	As on Half Year 30.09.2025 Unaudited	As at 31.3.2025 Audited
1	ASSETS		
1	Non-Current Assets		
	(a) Property, Plant and Equipment	13.14	123.03
	(b) Financial Assets		
	(i) Investments	60.75	60.75
	(ii) Other Financials Assets/Loans	13,734.18	25,081.23
	(c) Deferred Tax Assets	87.88	87.88
	Total Non-Current Assets	13,895.95	25,352.89
2	Current Assets		
	(a) Financial Assets		
	(i) Cash & Cash Equivalents	144.94	1,06,227.80
	(ii) Bank balances other than (i) above		-
	(b) Trade and Other Receivable	5,187.46	-
	(b) Other Current Assets		-
	(c) Current Tax Assets	1,350.00	1,917.83
	Total Current Assets	6,682.40	1,08,145.63
	TOTAL ASSETS	20,578.35	1,33,498.52
2	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity Share Capital	15,000.00	15,000.00
	(b) Other Equity	-624.29	1,16,446.23
	Total Equity	14,375.71	1,31,446.23
2	Liabilities		
1	Non-Current Liabilities		
	(A) Financial Liabilities		
	(a) Deferred Tax Liabilities (Net)		-
	(b) Long Term Borrowings/Loans	-	-
2	Current Liabilities		
	(a) Financial Liabilities		
	(i) Other Financial Liabilities		59.00
	(b) Short Term Borrowings/Loans	150.00	-
	(c) Trade Payable		
	(i) Total Outstanding due to creditors other than MSME	3,765.35	-
	(i) Total Outstanding due to MSME	-	-
	(b) Short Term Provisions	2,287.29	1,993.29
	Total Current Liabilities	6,202.64	2,052.29
	TOTAL EQUITY AND LIABILITIES	20,578.35	1,33,498.52

By order of the Board
FOR STARSOURCE MULTITRADE LIMITED
(Formerly known as CHEMO PHARMA
LABORATORIES LIMITED)

Mehta Ruchit P.

RUCHIT MEHTA
MD & CEO
DIN: 08810586

Date: 13.11.2025
Place: Mumbai



**STANDALONE CASH FLOW STATEMENT FOR THE HALF YEAR ENDED
AS ON 30TH SEPTEMBER, 2025**

(Rupees in Thousands)

PARTICULARS	Half Year 30.09.2025 Unaudited	Year Ended 31.3.2025 Audited
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit Before Tax and Extra-ordinary Items	-1,17,070.51	4,980.66
Adjustement for :		
Depreciation	0.00	54.48
Dividend Income	0.00	-487.12
Interest Income	-207.12	-5,179.20
Operating profit before working capital changes	-1,17,277.63	-631.18
Adjustement for		
Increase / (Decrease) in Other Current Liabilities	4,150.35	271.34
Decrease / (Increase) in Current Assets	-4,619.63	-471.38
Purchase of Property, Plant and Equipments	109.89	0.00
Cash Generated From Operations	-359.39	-200.04
Taxes Paid		-1,993.29
A. Cash Flow From Operating Activities	-1,17,637.02	-2,824.51
B. CASH FLOW FROM INVESTING ACTIVITIES		
Dividend Income	0.00	487.12
Interest Income	207.12	5,179.20
(Purchase) / Sale of Equity shares	0.00	43,913.75
(Investment)/Proceeds from Maturity of Fixed Deposits (Net)	0.00	55,000.00
Proceeds from maturity of fixed deposits with banks	0.00	0.00
Cash Flow From Investing Activities	207.12	1,04,580.07
C. CASH FLOW FROM FINANCING ACTIVITIES		
Decrease / (Increase) in Non-current Loans & Advances	11,347.05	-1,585.93
Proceeds from ICD Re-paid / (Given)		0.00
Cash Flow From Financing Activities	11,347.05	-1,585.93
Net Increase/(Decrease) in Cash and Cash Equivalents	-1,06,082.87	1,00,169.64
Opening Balance of Cash and Cash Equivalents	1,06,227.81	6,058.17
Closing Balance Of Cash and Cash Equivalents	144.94	1,06,227.81

By order of the Board
FOR STARSOURCE MULTITRADE LIMITED
(Formerly known as CHEMO PHARMA
LABORATORIES LIMITED)

Date: 13.11.2025
Place: Mumbai



Mehra Ruchit P.

RUCHIT MEHTA
MD & CEO
DIN: 08810586

Notes:

1. This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies . (Indian Accounting Standard) Accounting Rules, 2016.

2. The above Standalone Unaudited Financial Results for the Quarter & Half Year Ended 30.09.2025 have been reviewed by the Audit Committee in their Meeting held on 13.11.2025 and approved by the Board of Directors of its Meeting held on 13.11.2025. The Limited Review Report of Auditors M/s S S R V & Associates was also taken on record by the Board in its Meeting.

3 The Company is not having any Subsidiary Company.

4 The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.

Date: 13.11.2025
Place: Mumbai



FOR STARSOURCE MULTITRADE LIMITED
(Formerly known as CHEMO PHARMA
LABORATORIES LIMITED)

RUCHIT MEHTA
MD & CEO
DIN: 08810586

RECONCILIATION OF STANDALONE NET PROFIT FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2025**(Rs. In Thousands)**

PARTICULARS	STANDALONE					
	UNAUDITED QUARTER ENDED			UNAUDITED HALF YEAR ENDED		AUDITED YEAR ENDED
	30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025
Reconciliation of Profit After Tax as reported earlier:						
Net Profit / (Loss) for the Period (as per AS)	980.14	-1,18,050.65	2,358.00	-1,17,070.51	3,322.00	-1,837.00
Benefit / (Charge):						
Impact of Deferred Income (Government Grant) Amortized to Income	0.00		0.00	0.00	0.00	0.00
Impact of Fair Valuation of Financial Instruments	0.00	1,16,595.65	3,742.00	1,16,595.65	5,244.00	1,993.00
Impact of Actuarial Gain / Loss Taken OCI	0.00	0.00	0.00	0.00	0.00	0.00
Impact of Adjustment of Deferred Tax	0.00	0.00	0.00	0.00	0.00	-435.00
Impact of Adjustment of MAT Credit Entitlement	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit / (Loss) for the Period (as per AS)	980.14	-1,455.00	6,100.00	-474.86	8,566.00	-3,396.00

**OTHER INFORMATION- INTEGRATED FILING (FINANCIAL) -
FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2025**

(In accordance with the SEBI circular no . SEBI/ HO/ CFD/CFD-PoD-2/CIR/P/185 dated
December 31, 2024)

Sr. No	Particulars	Remarks
1	B. Statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc.	NOT APPLICABLE
2	C. Format for disclosing outstanding default on loans and debt securities	NOT APPLICABLE
3	D. Format for disclosure of related party transactions (applicable only for half yearly filings i.e. , 2nd and 4th quarter)	NOT APPLICABLE
4	E. Statement on impact of audit qualifications (for audit report with modified opinion) submitted along-with annual audited financial results (standalone and consolidated separately) (applicable only for annual filing i.e., 4th quarter)	NOT APPLICABLE



FOR STARSOURCE MULTITRADE LIMITED
(Formerly known as CHEMO PHARMA LABORATORIES LIMITED)

Mehta Ruchit P.

Date: 13.11.2025
Place: Mumbai

RUCHIT MEHTA
MD & CEO
DIN: 08810586

Independent Auditor, Review Report on Unaudited Standalone Financial Results for the quarter and Half year ended 30th September, 2025 of STARSOURCE MULTITRADE LIMITED (Formerly known as CHEMO PHARMA LABORATORIES LIMITED) pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 (2) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended.

To,

The Board of Directors,

STARSOURCE MULTITRADE LIMITED

(Formerly known as CHEMO PHARMA LABORATORIES LIMITED)

1. We have reviewed the accompanying statements of unaudited IND-AS Financial Results of **STARSOURCE MULTITRADE LIMITED (Formerly known as CHEMO PHARMA LABORATORIES LIMITED)** ("the Company") for the quarter and Half Year ended 30th September, 2025 ("The Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 read with Regulation 63(2) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended ("the Regulations").
2. This Statement which is the responsibility of the Company's Management and has been approved by the Board of Director's, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India and in compliance with Listing Obligations. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted and procedures performed as stated in paragraph 3 above has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34, prescribed under Section 133 of the companies Act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S S R V & Associates

Chartered Accountants

Firm Reg. No.: 135901W

Vishnu Kant Kabra

Partner

M. No.: 403437

Place: Mumbai

Date: 13th November, 2025

UDIN: 25403437BMIQMZ2849

